TIDMAZN
RNS Number : 3749L
AstraZeneca PLC
29 April 2020
29 April 2020 16:00 BST
Results of Annual General Meeting held on 29 April 2020
AstraZeneca PLC announced the results of the voting at its
Annual General Meeting (AGM) today. As proposed in the Notice of
AGM, all Resolutions were decided by poll vote. Resolutions 10 - 13
were passed as special resolutions; all other resolutions were
passed as ordinary resolutions.
RESOLUTION VOTES FOR % OF VOTES % OF VOTES CAST IN TOTAL VOTES
VOTES AGAINST VOTES TOTAL VOTES WITHHELD
CAST CAST CAST AS
A % OF
ISSUED
SHARE
CAPITAL
To receive the
Company's Accounts,
the Reports of the
Directors and Auditor
and the Strategic
Report for the year
1 ended 31 December 2019 1,061,180,101 99.92 872,215 0.08 1,062,052,316 80.93% 7,121,452
----------------------- -------------- -------- ------------ --------- -------------- -------- -----------
2 To confirm dividends 1,058,995,786 99.10 9,598,531 0.90 1,068,594,317 81.43% 579,469
----------------------- -------------- -------- ------------ --------- -------------- -------- -----------
3 To reappoint
PricewaterhouseCoopers
LLP as Auditor 1,068,300,235 99.97 312,449 0.03 1,068,612,684 81.43% 560,776
----------------------- -------------- -------- ------------ --------- -------------- -------- -----------
4 To authorise the
Directors to agree the
remuneration of the
Auditor 1,067,398,628 99.90 1,086,858 0.10 1,068,485,486 81.42% 687,961
----------------------- -------------- -------- ------------ --------- -------------- -------- -----------
5a To re-elect Leif
Johansson as a
Director 1,065,113,167 99.69 3,276,071 0.31 1,068,389,238 81.42% 784,805
----------------------- -------------- -------- ------------ --------- -------------- -------- -----------
To re-elect Pascal
5b Soriot as a Director 1,067,248,723 99.90 1,033,124 0.10 1,068,281,847 81.41% 892,364
----------------------- -------------- -------- ------------ --------- -------------- -------- -----------
To re-elect Marc
5c Dunoyer as a Director 1,060,164,242 99.25 8,056,265 0.75 1,068,220,507 81.40% 952,979
----------------------- -------------- -------- ------------ --------- -------------- -------- -----------
5d To re-elect
Geneviève Berger
as a Director 882,846,920 83.06 179,994,848 16.94 1,062,841,768 80.99% 6,331,650
----------------------- -------------- -------- ------------ --------- -------------- -------- -----------
5e To re-elect Philip
Broadley as a Director 1,066,048,992 99.79 2,190,705 0.21 1,068,239,697 81.41% 933,713
----------------------- -------------- -------- ------------ --------- -------------- -------- -----------
5f To re-elect Graham
Chipchase as a
Director 1,062,682,507 99.48 5,520,936 0.52 1,068,203,443 81.40% 969,967
----------------------- -------------- -------- ------------ --------- -------------- -------- -----------
5g To elect Michel
Demaré as a
Director 1,066,252,259 99.82 1,969,593 0.18 1,068,221,852 81.40% 951,558
----------------------- -------------- -------- ------------ --------- -------------- -------- -----------
5h To re-elect Deborah
DiSanzo as a Director 1,067,836,362 99.97 351,091 0.03 1,068,187,453 81.40% 985,957
----------------------- -------------- -------- ------------ --------- -------------- -------- -----------
To re-elect Sheri
5i McCoy as a Director 1,064,329,862 99.64 3,890,368 0.36 1,068,220,230 81.40% 951,792
----------------------- -------------- -------- ------------ --------- -------------- -------- -----------
To re-elect Tony Mok
5j as a Director 1,067,117,370 99.90 1,066,669 0.10 1,068,184,039 81.40% 989,371
----------------------- -------------- -------- ------------ --------- -------------- -------- -----------
5k To re-elect Nazneen
Rahman as a Director 1,067,376,963 99.92 821,467 0.08 1,068,198,430 81.40% 973,592
----------------------- -------------- -------- ------------ --------- -------------- -------- -----------
5l To re-elect Marcus
Wallenberg as a
Director 955,082,665 89.42 113,060,725 10.58 1,068,143,390 81.40% 1,030,019
----------------------- -------------- -------- ------------ --------- -------------- -------- -----------
6 To approve the Annual
Report on Remuneration
for the year ended 31
December 2019 1,032,308,145 96.65 35,747,783 3.35 1,068,055,928 81.39% 1,118,038
----------------------- -------------- -------- ------------ --------- -------------- -------- -----------
7 To approve the
Directors'
Remuneration Policy 972,774,742 94.71 54,292,376 5.29 1,027,067,118 78.27% 42,106,679
----------------------- -------------- -------- ------------ --------- -------------- -------- -----------
8 To authorise limited
political donations 1,038,907,152 97.75 23,872,400 2.25 1,062,779,552 80.99% 6,394,668
----------------------- -------------- -------- ------------ --------- -------------- -------- -----------
9 To authorise the
Directors to allot
shares 910,654,650 85.26 157,472,093 14.74 1,068,126,743 81.40% 1,046,979
----------------------- -------------- -------- ------------ --------- -------------- -------- -----------
10 To authorise the
Directors to disapply
pre-emption rights 1,058,066,972 99.23 8,200,338 0.77 1,066,267,310 81.26% 2,906,339
----------------------- -------------- -------- ------------ --------- -------------- -------- -----------
11 To authorise the
Directors to further
disapply pre-emption
rights for
acquisitions and
specified
capital investments 1,054,711,677 98.92 11,513,414 1.08 1,066,225,091 81.25% 2,948,557
----------------------- -------------- -------- ------------ --------- -------------- -------- -----------
12 To authorise the
Company to purchase
its own shares 1,051,131,060 98.41 16,950,800 1.59 1,068,081,860 81.39% 1,091,896
----------------------- -------------- -------- ------------ --------- -------------- -------- -----------
13 To reduce the notice
period for general
meetings 998,062,805 93.44 70,101,553 6.56 1,068,164,358 81.40% 1,008,865
----------------------- -------------- -------- ------------ --------- -------------- -------- -----------
14 To approve the 2020
Performance Share Plan 1,010,149,491 95.66 45,877,396 4.34 1,056,026,887 80.48% 13,147,356
----------------------- -------------- -------- ------------ --------- -------------- -------- -----------
Issued capital
As at 27 April 2020, the number of issued shares of the Company
was 1,312,240,429 ordinary shares, which was the total number of
shares entitling the holders to attend and vote for or against all
of the resolutions at the AGM. In accordance with the Company's
Articles of Association, on a poll every member present in person
or by proxy has one vote for every share held.
AstraZeneca
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development and commercialisation of prescription medicines,
primarily for the treatment of diseases in three therapy areas -
Oncology, Cardiovascular, Renal and Metabolism, and Respiratory.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries
and its innovative medicines are used by millions of patients
worldwide. Please visit astrazeneca.com and follow the Company on
Twitter @ AstraZeneca .
Contacts
For details on how to contact the Investor Relations Team,
please click here. For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
RAGPPURCCUPUGCB
(END) Dow Jones Newswires
April 29, 2020 11:00 ET (15:00 GMT)
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Sep 2023 to Sep 2024
